Beijing Hotgen Biotech Co Ltd (688068) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Beijing Hotgen Biotech Co Ltd (688068) has a cash flow conversion efficiency ratio of 0.001x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥3.05 Million ≈ $446.80K USD) by net assets (CN¥2.93 Billion ≈ $428.68 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Beijing Hotgen Biotech Co Ltd defensive liquidity buffer to measure how many days the company can operate on defensive assets alone.
Beijing Hotgen Biotech Co Ltd - Cash Flow Conversion Efficiency Trend (2016–2024)
This chart illustrates how Beijing Hotgen Biotech Co Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Beijing Hotgen Biotech Co Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Beijing Hotgen Biotech Co Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Sansteel MinGuang Co Ltd Fujian
SHE:002110
|
0.114x |
|
TA-I Technology Co Ltd
TW:2478
|
0.016x |
|
Siam Global House Public Company Limited
BK:GLOBAL
|
0.245x |
|
Wuxi Huadong Heavy Machinery Co Ltd
SHE:002685
|
0.042x |
|
Zimplats Holdings Ltd
AU:ZIM
|
0.089x |
|
Upwork Inc
NASDAQ:UPWK
|
0.101x |
|
eXp World Holdings Inc
NASDAQ:EXPI
|
0.123x |
|
SINOTRANS LTD H YC 1
F:SIY
|
0.020x |
Annual Cash Flow Conversion Efficiency for Beijing Hotgen Biotech Co Ltd (2016–2024)
The table below shows the annual cash flow conversion efficiency of Beijing Hotgen Biotech Co Ltd from 2016 to 2024. For the full company profile with market capitalisation and key ratios, see Beijing Hotgen Biotech Co Ltd (688068) total market value.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | CN¥3.07 Billion ≈ $449.84 Million |
CN¥-37.16 Million ≈ $-5.44 Million |
-0.012x | -59.91% |
| 2023-12-31 | CN¥3.36 Billion ≈ $491.39 Million |
CN¥-25.39 Million ≈ $-3.71 Million |
-0.008x | -102.59% |
| 2022-12-31 | CN¥3.35 Billion ≈ $490.75 Million |
CN¥978.75 Million ≈ $143.22 Million |
0.292x | -68.28% |
| 2021-12-31 | CN¥2.87 Billion ≈ $420.53 Million |
CN¥2.64 Billion ≈ $386.97 Million |
0.920x | +317.43% |
| 2020-12-31 | CN¥746.79 Million ≈ $109.28 Million |
CN¥164.62 Million ≈ $24.09 Million |
0.220x | +638.85% |
| 2019-12-31 | CN¥649.30 Million ≈ $95.01 Million |
CN¥19.37 Million ≈ $2.83 Million |
0.030x | -88.59% |
| 2018-12-31 | CN¥210.44 Million ≈ $30.79 Million |
CN¥55.04 Million ≈ $8.05 Million |
0.262x | +84.21% |
| 2017-12-31 | CN¥161.65 Million ≈ $23.65 Million |
CN¥22.95 Million ≈ $3.36 Million |
0.142x | -59.17% |
| 2016-12-31 | CN¥130.98 Million ≈ $19.17 Million |
CN¥45.54 Million ≈ $6.66 Million |
0.348x | -- |
About Beijing Hotgen Biotech Co Ltd
Beijing Hotgen Biotech Co., Ltd. engages in the research, development, manufacture, and sale of medical and public safety inspection products of in-vitro diagnostic products in the field of biomedicine. It offers public safety solutions such as drug tasting, customs disease control, bioterrorism and food safety solutions. The company also provides clinical diagnostics and product solutions, inclu… Read more